期刊文献+

促红细胞生成素β与α治疗慢性血液透析患者肾性贫血的疗效观察 被引量:1

下载PDF
导出
摘要 目的比较促红细胞生成素β与α治疗慢性血液透析患者肾陛贫血的有效性。方法选取2012年7月至2013年6月慢性血液透析患者72例,将其随机分为3组:24例由静脉注射促红细胞生成素α改为静脉注射促红细胞生成素B(A组),24例由静脉注射促红细胞生成素α改为皮下注射促红细胞生成素β(B组),剩余24例患者继续静脉注射促红细胞生成素α(C组)。所有入选患者透析后均使用促红细胞生成素,5000IU(1支)/次,2次/周。结果比较各组间治疗前、治疗后3、6个月平均血红蛋白(Hb)水平及红细胞压积(Hct)水平,A组与C组患者治疗后比较血红蛋白差异无统计学意义(P〉0.05),B组患者Hb水平高于A组且差异有统计学意义(P〈0.05)。结论促红细胞生成素β与α在血液透析患者肾性贫血治疗中有相似的疗效,在6个月的研究期间促红细胞生成素β皮下注射方法较静脉注射方法显示出更好的疗效。
出处 《浙江临床医学》 2015年第3期417-418,共2页 Zhejiang Clinical Medical Journal
  • 相关文献

参考文献11

  • 1Go AS,Chertow GM,Fan D,et al. Chronic kidney disease and the risks of death,cardiovascular events,and hospitalization.N Engl J Med, 2004,351(13):1296-1305. 被引量:1
  • 2Kidney Disease Outcomes Quality Initiative,National Kidney Foundation.KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis,2006,47(5 Suppl 3):S11-S145. 被引量:1
  • 3Silverberg DS,Wexler D,Sheps D,et al. The effect of correction of mild anemia in severe,resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study.J Am Coll Cardiol,2001,37(7):1775-1780. 被引量:1
  • 4IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. AmJ Kidney Dis,2001,37(1 Suppl 1):S182-S238. 被引量:1
  • 5Locatelli F,Aljama P,Barany P,et al. Revised European best practice guidehnes for the management of anaemia in patients with chronic renal failure.Nephrol Dial Transplant,2004,19 (Suppl 2):il-i47. 被引量:1
  • 6Beiraghdar F,Panahi Y,Einollahi B,et al. Investigation of the efficacy of a biogenetic recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi- center clinical trial. Clin Lab,2012,58(7-8):737-745. 被引量:1
  • 7Ostrvica E,Mesic E,Ostrvica D,et al. Effectiveness of treating the renal anemia in chronic hemodialyzed patients by epoietin alpha and beta.Med Arh,2010,64(1):4-6. 被引量:1
  • 8Grzeszczak W,Sulowicz W,Rutkowski B,et al. The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin beta in peritoneal dialysis patients with chronic renal anaemia. Nephrol Dial Transplant,2005,20(5) :936-44. 被引量:1
  • 9Thomas Rath,Robert A. Mactier, Thomas Weinreich,et al. Effectiveness and safety of recombinant human erythropoietin beta in maintaining common haemoglobin targets in routine clinical practice in Europe: the GAIN study.Current Medical Research And Opinion, 2009, 25(4): 961-970. 被引量:1
  • 10Edin Ostrvica,Enisa Mesic,Dzenana Ostrvica,et al. Effectiveness of Treating the Renal Anemia in Chronic Hemodialyzed Patients by Epoietin Alpha and Beta.MED ARH,2010,64(1):4-6. 被引量:1

同被引文献12

引证文献1

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部